Summit Therapeutics Inc. – NASDAQ:SMMT
Summit Therapeutics stock price today
$25.56
+7.34
+40.36%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 17 hours
Summit Therapeutics stock price monthly change
+112.98%
month
Summit Therapeutics stock price quarterly change
+112.98%
quarter
Summit Therapeutics stock price yearly change
+559.78%
year
Summit Therapeutics key metrics
Market Cap | 13.23B |
Enterprise value | 459.72M |
P/E | -4.71 |
EV/Sales | 651.43 |
EV/EBITDA | 340.58 |
Price/Sales | 438.33 |
Price/Book | 2.44 |
PEG ratio | -0.04 |
EPS | -0.16 |
Revenue | N/A |
EBITDA | -87.47M |
Income | -116.02M |
Revenue Q/Q | N/A |
Revenue Y/Y | -100% |
Profit margin | -11.16% |
Oper. margin | -7338.76% |
Gross margin | 33.3% |
EBIT margin | -7338.76% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSummit Therapeutics stock price history
Summit Therapeutics stock forecast
Summit Therapeutics financial statements
Average Price Target
$35
Potential upside: 36.93%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 235K | -14.71M | -6262.55% |
|---|---|---|---|
| Sep 2023 | 0 | -21.26M | |
| Dec 2023 | -235K | -36.56M | 15560.43% |
| Mar 2024 | 0 | -43.47M |
| Jun 2023 | 237372000 | 117.77M | 49.62% |
|---|---|---|---|
| Sep 2023 | 218476000 | 119.09M | 54.51% |
| Dec 2023 | 202949000 | 125.25M | 61.72% |
| Mar 2024 | 176781000 | 132.57M | 74.99% |
| Jun 2023 | -29.27M | 207K | -80K |
|---|---|---|---|
| Sep 2023 | -14.89M | -3.48M | 229K |
| Dec 2023 | -19.45M | 60.56M | 6.25M |
| Mar 2024 | -30.13M | 19.87M | 485K |
Summit Therapeutics alternative data
| Aug 2023 | 76 |
|---|---|
| Sep 2023 | 76 |
| Oct 2023 | 76 |
| Nov 2023 | 76 |
| Dec 2023 | 76 |
| Jan 2024 | 76 |
| Feb 2024 | 76 |
| Mar 2024 | 105 |
| Apr 2024 | 105 |
| May 2024 | 105 |
| Jun 2024 | 105 |
| Jul 2024 | 105 |
Summit Therapeutics other data
2.58%
-2.84%
of SMMT is owned by hedge funds
4.99M
-3.05M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Oct 2023 | 2976190 | 0 |
| Dec 2023 | 20400 | 0 |
| Mar 2024 | 210321 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | ZANGANEH MAHKAM director, officer: Chief Execut.. | Common Stock | 34,321 | $3.72 | $127,674 | ||
Purchase | ZANGANEH MAHKAM director, officer: Chief Execut.. | Common Stock | 26,000 | $3.72 | $96,720 | ||
Purchase | ZANGANEH MAHKAM director, officer: Chief Execut.. | Common Stock | 20,000 | $3.71 | $74,200 | ||
Purchase | ZANGANEH MAHKAM director, officer: Chief Execut.. | Common Stock | 30,000 | $3.75 | $112,500 | ||
Purchase | DHINGRA ANKUR officer: Chief Financial Officer | Common Stock | 100,000 | $3.75 | $375,000 | ||
Purchase | DHINGRA ANKUR officer: Chief Financial Officer | Common Stock | 19,700 | $2.17 | $42,749 | ||
Purchase | DHINGRA ANKUR officer: Chief Financial Officer | Common Stock | 700 | $2.15 | $1,505 | ||
Purchase | SONI MANMEET SINGH director, officer.. | Common Stock | 2,976,190 | $1.68 | $4,999,999 | ||
Purchase | ZANGANEH MAHKAM director, officer: Co-CEO & Pre.. | Common Stock | 13,497,258 | $1.05 | $14,172,121 | ||
Purchase | ZANGANEH MAHKAM director, officer: Co-Chief Exe.. | Common Stock | 804,672 | $1.05 | $844,906 |
| Quarter | Transcript |
|---|---|
| Q1 2024 1 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 20 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Mahkam Zanganeh D.D.S., M.B.A., MBA (1970) Chief Operating Officer & Director | $459,380 |
Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One
Summit Therapeutics: Market Overreaction Creates Opportunity
Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release
Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates
Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success
Pfizer Thinks Bigger With 3SBio Deal
Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition
Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
-
What's the price of Summit Therapeutics stock today?
One share of Summit Therapeutics stock can currently be purchased for approximately $25.56.
-
When is Summit Therapeutics's next earnings date?
Unfortunately, Summit Therapeutics's (SMMT) next earnings date is currently unknown.
-
Does Summit Therapeutics pay dividends?
No, Summit Therapeutics does not pay dividends.
-
How much money does Summit Therapeutics make?
Summit Therapeutics has a market capitalization of 13.23B.
-
What is Summit Therapeutics's stock symbol?
Summit Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "SMMT".
-
What is Summit Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Summit Therapeutics?
Shares of Summit Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Summit Therapeutics's key executives?
Summit Therapeutics's management team includes the following people:
- Dr. Mahkam Zanganeh D.D.S., M.B.A., MBA Chief Operating Officer & Director(age: 55, pay: $459,380)
-
How many employees does Summit Therapeutics have?
As Jul 2024, Summit Therapeutics employs 105 workers.
-
When Summit Therapeutics went public?
Summit Therapeutics Inc. is publicly traded company for more then 10 years since IPO on 5 Mar 2015.
-
What is Summit Therapeutics's official website?
The official website for Summit Therapeutics is summittxinc.com.
-
Where are Summit Therapeutics's headquarters?
Summit Therapeutics is headquartered at One Broadway, Cambridge, MA.
-
How can i contact Summit Therapeutics?
Summit Therapeutics's mailing address is One Broadway, Cambridge, MA and company can be reached via phone at +61 75147149.
-
What is Summit Therapeutics stock forecast & price target?
Based on 4 Wall Street analysts` predicted price targets for Summit Therapeutics in the last 12 months, the avarage price target is $35. The average price target represents a 36.93% change from the last price of $25.56.
Summit Therapeutics company profile:
Summit Therapeutics Inc.
summittxinc.comExchange:
NASDAQ
Full time employees:
105
Industry:
Biotechnology
Sector:
Healthcare
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
One Broadway
Cambridge, MA 02142
Cambridge, MA 02142
CIK: 0001599298
ISIN: US86627T1088
CUSIP: 86627T108
